In addition, concomitant blockade of CXCL13 and B cell activating factor receptor (BAFFR) led to reduced salivary gland inflammation, total serum antibodies and anti-nuclear autoantibodies (ANA)-specific IgG autoantibody titers, along with preventing xerostomia development in a pSS mouse model (161). The gene discussed is TNFRSF13C; the disease is xerostomia.